4D pharma plc – NASDAQ:LBPS
4D pharma stock price today
4D pharma stock price monthly change
4D pharma stock price quarterly change
4D pharma stock price yearly change
4D pharma key metrics
Market Cap | N/A |
Enterprise value | 30.20M |
P/E | -4.08 |
EV/Sales | 219.66 |
EV/EBITDA | -3.98 |
Price/Sales | 203.72 |
Price/Book | 0.86 |
PEG ratio | N/A |
EPS | -0.3 |
Revenue | 137.5K |
EBITDA | -7.57M |
Income | -6.86M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -4991.27% |
Oper. margin | -6009.45% |
Gross margin | 100% |
EBIT margin | -6009.45% |
EBITDA margin | -5512.36% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for free4D pharma stock price history
4D pharma stock forecast
4D pharma financial statements
| Jun 2020 | 137.5K | -6.86M | -4991.27% |
|---|
| Jun 2020 | 39946000 | 8.48M | 21.25% |
|---|---|---|---|
| Dec 2020 | 35421000 | 7.45M | 21.04% |
| Jun 2021 | 47647000 | 7.98M | 16.76% |
| Dec 2021 | 58794000 | 26.37M | 44.87% |
| Mar 2017 | -4.29M | -25.25K | 0 |
|---|---|---|---|
| Jun 2017 | -4.29M | -25.25K | 0 |
| Dec 2017 | -5.73M | 6.85M | 0 |
| Jun 2020 | 0 | 2.5K | 10.14M |
4D pharma alternative data
| Aug 2023 | 106 |
|---|---|
| Sep 2023 | 106 |
| Oct 2023 | 106 |
| Nov 2023 | 106 |
| Dec 2023 | 106 |
| Jan 2024 | 106 |
| Feb 2024 | 106 |
| Mar 2024 | 106 |
| Apr 2024 | 106 |
| May 2024 | 106 |
| Jun 2024 | 106 |
| Jul 2024 | 106 |
4D pharma other data
| Patent |
|---|
Application Filling date: 2 Dec 2021 Issue date: 18 Aug 2022 |
Application Filling date: 24 Feb 2021 Issue date: 4 Nov 2021 |
Application Filling date: 24 Feb 2021 Issue date: 28 Oct 2021 |
Application Filling date: 4 Dec 2020 Issue date: 21 Oct 2021 |
Application Filling date: 30 Sep 2020 Issue date: 1 Jul 2021 |
Grant Filling date: 19 Feb 2020 Issue date: 6 Apr 2021 |
Grant Filling date: 19 Feb 2020 Issue date: 30 Mar 2021 |
Grant Filling date: 4 Sep 2019 Issue date: 26 Jan 2021 |
Application Filling date: 19 Feb 2020 Issue date: 12 Nov 2020 |
Application Filling date: 19 Feb 2020 Issue date: 12 Nov 2020 |
| Insider | Compensation |
|---|---|
Dr. Alexander James Stevenson Ph.D. (1972) Chief Scientific Officer & Executive Director | $137,500 |
Mr. Duncan Joseph Peyton (1970) Chief Executive Officer & Executive Director | $137,500 |
-
What's the price of 4D pharma stock today?
One share of 4D pharma stock can currently be purchased for approximately $1.65.
-
When is 4D pharma's next earnings date?
Unfortunately, 4D pharma's (LBPS) next earnings date is currently unknown.
-
Does 4D pharma pay dividends?
No, 4D pharma does not pay dividends.
-
What is 4D pharma's stock symbol?
4D pharma plc is traded on the NASDAQ under the ticker symbol "LBPS".
-
What is 4D pharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of 4D pharma?
Shares of 4D pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are 4D pharma's key executives?
4D pharma's management team includes the following people:
- Dr. Alexander James Stevenson Ph.D. Chief Scientific Officer & Executive Director(age: 53, pay: $137,500)
- Mr. Duncan Joseph Peyton Chief Executive Officer & Executive Director(age: 55, pay: $137,500)
-
How many employees does 4D pharma have?
As Jul 2024, 4D pharma employs 106 workers.
-
When 4D pharma went public?
4D pharma plc is publicly traded company for more then 4 years since IPO on 22 Mar 2021.
-
What is 4D pharma's official website?
The official website for 4D pharma is 4dpharmaplc.com.
4D pharma company profile:
4D pharma plc
4dpharmaplc.comNASDAQ
106
Biotechnology
Healthcare
4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.
Leeds, LS1 2JZ
CIK: 0001830162
ISIN: US35085K1097
:
